Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
- PMID: 38696170
- PMCID: PMC11066699
- DOI: 10.1001/jamanetworkopen.2024.9305
Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
Erratum in
-
Error in Results.JAMA Netw Open. 2024 Jul 1;7(7):e2428489. doi: 10.1001/jamanetworkopen.2024.28489. JAMA Netw Open. 2024. PMID: 39046747 Free PMC article. No abstract available.
Abstract
Importance: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection.
Objective: To determine the comparative outcomes of empagliflozin and dapagliflozin on reducing the composite of all-cause mortality and hospitalizations in patients with heart failure.
Design, setting, and participants: This multicenter retrospective cohort study included patients with heart failure from August 18, 2021, and December 6, 2022, in the TriNetX Research Collaborative, a centralized database of deidentified electronic medical record data from a network of 81 health care organizations. Eligible patients had a diagnosis of heart failure, had never received an SGLT2 inhibitor previously, and were newly started on empagliflozin or dapagliflozin. Patients were followed up for 1 year.
Exposure: Initiation of dapagliflozin or empagliflozin.
Main outcomes and measures: The primary outcome was the time to the composite of all-cause mortality or hospitalization between study days 1 to 365. Kaplan-Meier analyses, hazard ratios (HRs), and 95% CIs were used to assess the primary outcome.
Results: Among 744 914 eligible patients, 28 075 began empagliflozin (15 976 [56.9%]) or dapagliflozin (12 099 [43.1%]). After nearest-neighbor matching for demographics, diagnoses, and medication use, there were 11 077 patients in each group. Of patients who received empagliflozin, 9247 (57.9%) were male, 3130 (19.6%) were Black individuals, and 9576 (59.9%) were White individuals. Similarly, of those who received dapagliflozin, 7439 (61.5%) were male, 2445 (20.2%) were Black individuals, and 7131 (58.9%) were White individuals. Patients receiving empagliflozin were less likely to experience the composite of all-cause mortality or hospitalization compared with those initiated on dapagliflozin (3545 [32.2%] vs 3828 [34.8%] events; HR, 0.90 [95% CI, 0.86-0.94]) in the year following SGLT2 inhibitor initiation and less likely to be hospitalized (HR, 0.90 [95% CI, 0.86-0.94]). All-cause mortality did not differ between exposure groups (HR, 0.91 [95% CI, 0.82-1.00]). There was no difference in mean hemoglobin A1c or adverse events between groups.
Conclusions and relevance: In this cohort study, patients who initiated empagliflozin were less likely to experience the composite of all-cause mortality or hospitalization compared with patients who started dapagliflozin. Additional studies are needed to confirm these finding.
Conflict of interest statement
Figures
Similar articles
-
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.Cardiovasc Diabetol. 2021 Oct 23;20(1):213. doi: 10.1186/s12933-021-01406-3. Cardiovasc Diabetol. 2021. PMID: 34688282 Free PMC article.
-
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.Cardiovasc Diabetol. 2019 Sep 24;18(1):120. doi: 10.1186/s12933-019-0919-9. Cardiovasc Diabetol. 2019. PMID: 31551068 Free PMC article.
-
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.Am J Cardiovasc Drugs. 2024 May;24(3):455-464. doi: 10.1007/s40256-024-00648-2. Epub 2024 Apr 30. Am J Cardiovasc Drugs. 2024. PMID: 38691312
-
The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.Ann Pharmacother. 2024 May;58(5):506-513. doi: 10.1177/10600280231189508. Epub 2023 Aug 5. Ann Pharmacother. 2024. PMID: 37542422 Review.
-
Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.Eur J Clin Pharmacol. 2024 Jul;80(7):951-963. doi: 10.1007/s00228-024-03660-2. Epub 2024 Mar 18. Eur J Clin Pharmacol. 2024. PMID: 38498097 Review.
Cited by
-
Error in Results.JAMA Netw Open. 2024 Jul 1;7(7):e2428489. doi: 10.1001/jamanetworkopen.2024.28489. JAMA Netw Open. 2024. PMID: 39046747 Free PMC article. No abstract available.
References
-
- Poole-Wilson PA, Swedberg K, Cleland JGF, et al. ; Carvedilol Or Metoprolol European Trial Investigators . Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7 - DOI - PubMed
-
- Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65-73. doi:10.1016/j.diabres.2019.04.008 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical